#BlossomHill

BlossomHill Therapeutics Falls Post-$150M IPO in Cautious Biotech Debut

BlossomHill Therapeutics' post-IPO decline highlights investor caution toward cancer drugmakers, with the $150 million debut faltering on U.S. exchanges as biotech sentiment…

BlossomHill's $150 Million IPO Priced, Backed by Janus Henderson

BlossomHill's $150 million IPO, backed by Janus Henderson, underscored biotech demand and could lift Janus Henderson's stock on the back of a…

BlossomHill Files for $132.8M IPO with Janus Henderson Backing

BlossomHill IPO filing aims to raise $132.8 million with backing from Janus Henderson, signaling confidence in public market debut.